There is good news for early breast cancer patients in China - the ideal tracer for sentinel lymph node biopsy has been approved to be launched in the market recently.

On February 23, the National Medical Products Administration released the latest drug approval documents on its official website. Guangdong Hepoer Pharmaceutical Co's Isosulfan Blue Injection, known as "博林兰®", was approved for marketing. 

The Isosulfan Blue Injection is a tracer used as an adjunct to lymphography. It was first launched in the market in the United States in 1981, and no manufacturer has been approved in China. It was declared a Class-3 generic drug by Hepoer in March 2022, and after approval, the product filled the gap in the domestic market.

Hepoer was established in 2013 at Zhongshan's National Health Technology Park. It primarily focuses on domestic "first generic drugs", Class-2 new drugs and innovative drugs. The company has mastery over key technologies in carbohydrate drug preparation and quality control, as well as chiral drug preparation. It has been consistently listed among the top 50 biotechnology innovation companies in the Guangdong-Hong Kong-Macao Greater Bay Area.